Citations

Clear

249 citation(s) found for "St-Denis, L".

Perioperative Anemia Development and Recovery in Adult Surgical Patients: An Observational Cohort Study
Snegovskikh, Denis , Morales Behaine, Juan J , Medina-Rincon, German J , Hanson, Andrew C , Robbins, Kellie A , Warner, Matthew A

Mayo Clinic

Anesthesia & Analgesia | October 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1213/ane.0000000000008365 | PMID 42854211 Get It

BACKGROUND: Anemia affects more than two billion people worldwide and is common among surgical patients. Despite growing recognition of the risks associated with preoperative anemia, we have limited understanding of the epidemiology of anemia development and recovery. METHODS: This is an observational cohort study of adults undergoing surgery at a large tertiary care medical center from August 2012 to July 2023. Hemoglobin concentrations were obtained preoperatively, during postoperative hospitalization, and through 12 months after surgery. Anemia was defined primarily using World Health Organization criteria (hemoglobin <12 g/dL in women, <13 g/dL in men) and secondarily with a gender-neutral threshold of <13 g/dL. Descriptive analyses summarize preoperative anemia prevalence, postoperative anemia prevalence and incidence, and post-hospitalization anemia recovery across demographic, clinical, and surgical features. RESULTS: 281,217 patients undergoing 423,066 procedures (51.9% among women) were included. Among those with available preoperative hemoglobin assessments (n = 308,959), 28.9% had anemia, with similar prevalence in men (29.5%) and women (28.4%) using World Health Organization (WHO) definitions, but with prevalence increasing to 51.0% in women when using the gender-neutral anemia definition. Preoperative anemia was most common in Black patients (44.0%) and in those ≥75 years (39.6%). Surgical subspecialties showed wide variation in preoperative anemia prevalence, ranging from 18.6% in spine surgery to 45.8% in vascular surgery. Among previously nonanemic patients admitted to the hospital postoperatively, 76.9% developed new postoperative anemia, with the highest incidence in cardiac surgery (97.5%). Women experienced more severe postoperative anemia than men. Overall, 81.1% of patients were anemic at hospital discharge. Recovery was gradual and incomplete: among those discharged with mild, moderate, or severe anemia, 28.5%, 51.9%, and 66.3%, respectively, remained anemic at 12 months. Among patients who were nonanemic preoperatively but developed new postoperative anemia, 29.3% remained anemic at 12 months. CONCLUSIONS: Preoperative and postoperative anemia are highly prevalent, and anemia frequently persists for months after hospitalization. Older adults, women, and Black patients bear a disproportionate burden. Despite this, anemia evaluations and treatments remain underutilized. These findings highlight substantial opportunities for patient blood management (PBM) programs to improve perioperative anemia detection, optimization, and post-discharge management.
African Genetic Similarity Is Associated with Reduced Inflammation and Enhanced Adaptive Immunity in Multiple Myeloma
Pilcher, William , Tang, Hongwei, Ferguson, Katherine, Foltz, Steven , Michaud, Marina E. , Satpathy, Sarthak , Shah, Nishi , Jin, Yuxin , Ohlstrom, Denis, Bakhtiari, Mojtaba , Acharya, Chaitanya R. , Gout, Alexander M. , Keats, Jonathan J. , Dhodapkar, Madhav V. , Avigan, David , Vij, Ravi, Kumar, Shaji , Cho, Hearn Jay , Vlachos, Ioannis S. , Ding, Li , Gnjatic, Sacha , Cole, Craig E. , Nooka, Ajay K. , Lonial, Sagar, Carpten, John, Baughn, Linda B. , Bhasin, Manoj

Mayo Clinic

Blood Journal | October 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2026033999 | PMID 42832384 Get It

The bone marrow immune microenvironment (BMME) is a critical factor in multiple myeloma (MM) pathogenesis. Despite higher incidence of MM among self-identified African Americans, the relationship between African genetic similarity and the BMME remains unclear. We present the largest analysis to date assessing the impact of Ancestry on the BMME in myeloma (N=320, including 64 with ≥50% African genetic similarity, AFR-High) leveraging our recently generated Immune Atlas. AFR-High was associated with enrichment of late T-effector cells, driven by rare cytotoxic CD4⁺ T cells, suggesting a distinct adaptive BMME. AFR-High exhibited expansion of late-differentiated adaptive NK cells with high cytotoxic GNLY and GZMH expression. AFR-High depicted reduced CD14⁺ monocytes, increased CD16⁺ non-classical monocytes, and expansion of macrophage-like monocyte populations with enrichment of metabolic adaptation, efferocytosis and phagocytic clearance programs, and immunoregulatory pathways. These findings reveal a shift from an innate inflammatory immune landscape toward adaptive cytotoxic and immunoregulatory remodeling associated with African genetic similarity in MM.
Management of erythromelalgia: a narrative review and expert opinion
Aldhalaan, Jumana , Sartori-Valinotti, Julio C., Davis, Mark D.P. , Sandroni, Paula , Davis, Mark Denis P., Sartori‐Valinotti, Julio C. , Sandroni, Paola

Mayo Clinic

Expert Opinion on Pharmacotherapy | September 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-12

10.1080/14656566.2026.2734121 | PMID 42732084 Get It

Integrated coding-noncoding genome annotation expands single-cell transcriptomic discovery and identifies clinically relevant noncoding RNAs in multiple myeloma
Bakhtiari, Mojtaba , Henderson, Edward, Ferguson, Katherine , Pilcher, William C., Gonzalez-Kozlova, Edgar, Karagkouni, Dimitra, Matulis, Shannon M. , Acharya, Chaitanya R., Avigan, David, Vij, Ravi, Parekh, Samir, Ding, Li, Kumar, Shaji, Nooka, Ajay, Mulligan, George, Lonial, Sagar, Bhasin, Manoj, Michaud, Marina E. , Ohlstrom, Denis , Satpathy, Sarthak , Pilcher, William , Gonzalez‐Kozlova, Edgar , Karagkouni, Dimitra , Acharya, Chaitanya R. , Avigan, David , Vij, Ravi , Parekh, Samir , Cho, Hearn Jay , Vlachos, Ioannis S. , Kumar, Shaji , Gnjatic, Sacha , Nooka, Ajay K. , Lonial, Sagar , Boise, Lawrence , Bhasin, Manoj K

Mayo Clinic

No container title available | August 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.09.743753 Get It

Abstract Although the human genome encodes a vast repertoire of noncoding RNAs that regulate gene expression, the noncoding genome remains underexplored due to technical challenges. Specifically, during transcriptomic sequencing data alignment, the overlap between noncoding and coding loci can create ambiguous read alignments that are subsequently discarded from downstream analysis. For this reason, most of the noncoding genome is excluded from standard genomic annotations used for sequencing alignment. To address this challenge and enable concurrent profiling of the coding and noncoding transcriptome, we systematically integrated standard coding (GENCODE) and noncoding (LncBook) genome annotations, preserving coding gene annotations and removing overlapping noncoding regions. The resulting integrated genome annotation expanded the number of annotated noncoding genes from 40,785 to 138,296 while preserving all coding genes and reducing ambiguous read assignment. To evaluate the utility of our integrated genome annotation for uncovering novel, biologically relevant noncoding RNAs (ncRNAs), we realigned CD138-positive bulk RNA-seq (N = 942) and CD138-negative single-cell RNA-seq (N = 478) data from the MMRF CoMMpass study, generating a comprehensive coding-noncoding atlas of the myeloma bone marrow microenvironment with noncoding genes representing 51% of highly variable genes and displaying significant cell type specificity. Tumor expression profiling based on this integrated profiling identified 15 clusters, including two enriched for amp(1q21) or t(4;14) and associated with shorter progression-free survival (PFS). Differential expression and systematic filtering yielded 19 candidate high-risk ncRNAs, including previously uncharacterized ENSG00000310209 , which was associated with poor PFS (HR = 1.141, P = 0.0025), increased IRF4 activity, Wnt pathway activation, CCL5 signaling, and the accumulation of anergic-like CD8+ T cells. These findings establish integrated coding-noncoding analysis as a strategic approach for discovering functional ncRNAs from transcriptomic sequencing data.
Outcomes of Immune Check Point Inhibitor Use in US Veterans With Pre‐Existing Idiopathic Inflammatory Myopathies: Case Series and Literature Review
Крутько, Д. М. , Rubino, Selene , Kunkel, Gary, Rojas, Jorge, Patel, Shardool, Cannon, Grant W. , Braaten, Tawnie , Krutko, Denis , Walsh, Jessica A , Cannon, Grant W , Sauer, Brian C.

Mayo Clinic

ACR Open Rheumatology | August 10, 2026 | Volume: 8 | Issue: 8 | Pages: No page available

10.1002/acr2.90127 | PMID 42572441 Get It

Objective Our objective was to identify and describe the clinical characteristics and outcomes in patients with pre‐existing idiopathic inflammatory myopathies (IIMs) in the Veterans Health Administration (VHA) treated with immune checkpoint inhibitors (ICIs). Methods All veterans receiving ICI infusions were identified. Patients with at least two International Classification of Disease codes for IIM before first ICI infusion underwent chart review to identify patients with confirmed IIM by American College of Rheumatology/EULAR criteria. The demographics, cancer diagnoses, laboratory findings, clinical course, and mortality rates were reported. IIM cases were also reviewed to determine if patients developed IIM flare following ICI treatment. Results We identified 29,539 veterans who received at least one ICI infusion in the VHA between June 6, 2011, and February 14, 2023. The eight patients with confirmed IIM before ICI treatment were mostly White men with an average age of 71.7 years at first ICI infusion. The IIM diagnoses were dermatomyositis in three patients, polymyositis in two, antisynthetase syndrome in two, and one rheumatoid arthritis (RA)/myositis overlap. Cancer diagnoses were lung (two), melanoma (two), head and neck (two), kidney/other urinary (one), and mesothelioma (one). Diagnosis of IIM was made on average 3.1 years before ICI treatment. One patient had an IIM flare after ICI. No IIM flares were identified in other patients. Conclusion Our findings show that an IIM flare after ICI therapy can occur, but most patients did not develop a flare. These observations suggest ICIs can be considered as an option in patients with cancer with IIM with shared decision‐making and close monitoring.
Multicentre randomised comparative effectiveness trial of cleavage-stage versus blastocyst-stage embryo transfer in patients with few embryos (PRECISE): implementation of a study protocol in reproductive medicine
Neuhausser, Werner , Vaughan, Denis A. , Sakkas, Denny, Anchan, Raymond M. , Hornstein, Mark D., Reeder, Harrison T, Barnhart, Kurt T, Cedars, Marcelle I. , Halıcıgil, Cihan , Beck, Michelle, Marsh, Erica E. , Gracia, Clarisa R. , Rosenwaks, Zev, Rabideau, Dustin J. , Trial, Stakeholder Advisory Group and Study Investigators of the PRECISE, Trial, Data and Safety Monitoring Board and Study Investigators of the PRECISE, Neuhausser, Werner M , Sakkas, Denny , Penzias, Alan S. , Reeder, Harrison Thomas , Barnhart, Kurt T. , Stewart, Elizabeth A. , Taylor, Hugh S. , Hacker, Michele R. , Rosenwaks, Zev, Williams, Zev

Mayo Clinic

BMJ Open | August 4, 2026 | Volume: 16 | Issue: 8 | Pages: e107903

10.1136/bmjopen-2025-107903 | PMID 42552004 Get It

Background With improvements in in vitro culture techniques, there has been a steady shift in practice to transfer in vitro fertilisation (IVF) embryos at the blastocyst-stage to increase pregnancy rates per embryo transfer (ET) and reduce the risk of multiple pregnancy. In patients with fewer embryos (≤5 zygotes), fresh cleavage-stage ET is still commonly performed to reduce the risk of cycle cancellation if no embryo survives to the blastocyst-stage in vitro. However, evidence for improved outcomes with cleavage-stage embryo transfer in this subgroup of patients is lacking. We will compare blastocyst-stage to cleavage-stage ET with regard to cumulative live birth rates (CLBR) per oocyte retrieval and other patient-centred cycle outcomes in patients with ≤5 zygotes. Methods and analysis Multicentre, randomised pragmatic comparative effectiveness trial with superiority design comparing blastocyst-stage to cleavage-stage ET in patients with ≤5 zygotes. This trial will enrol and randomise 1126 women aged 18–44 undergoing IVF to either fresh cleavage-stage or blastocyst-stage ET at eleven IVF centres. Surplus embryos will be vitrified at the blastocyst-stage. The primary outcome is the CLBR per oocyte retrieval. Secondary outcomes include: multiple pregnancy, pregnancy loss <20 weeks and cycle cancellation. Exploratory outcomes include: live birth per fresh ET, ectopic pregnancy, time to pregnancy, stillbirth, preterm birth, financial burden, patient distress and facilitators and barriers for patient involvement and implementation. All primary analyses will be conducted according to the intent-to-treat principle. We also will report per-protocol analyses as a sensitivity analysis. A multidisciplinary stakeholder team, including a 5-patient stakeholder panel, will participate in study design, conduct and oversight. Ethics and dissemination The Institutional Review Board at Beth Israel Deaconess Medical Center (BIDMC) provides central regulatory oversight. Results will inform timing of embryo transfer in patients with ≤5 zygotes and will be disseminated through academic publications, meeting presentations and communications to advocacy groups and patient participants. Trial registration number NCT06746129 .
Natural Microbial Experience Increases Infiltration of T Cells in the Brains of Alzheimer’s Disease Mice 2258422
Roscoe, Donna, Fryer, John, Roscoe, Donna, Fryer, John Denis

Mayo Clinic

The Journal of Immunology | July 28, 2026 | Volume: 215 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkag141.586 Get It

Abstract Introduction The immune environment of the brain plays a major role in neurodegenerative conditions such as Alzheimer’s disease. The abnormally clean facilities in which laboratory mice are kept limit immune experience and cause major concerns regarding the translatability of research to humans. These facilities, although not germ-free, lack the normal exposures to diverse commensal and environmental microorganisms experienced by mice in the wild or diverse environments such as a pet store. By breeding inbred lab mice that have previously experienced exposure to the dirty bedding of pet store mice, we can generate “bred dirty” mice with immune systems that mirror those of adult humans more closely. It is unclear whether these immune changes extend to the brain and whether this plays a role in neurodegenerative disease. Methods We used the P301s transgenic mouse model of Alzheimer’s disease that accumulates age-dependent tau pathology. We exposed these mice to dirty bedding obtained from pet store mice, and bred them to establish a line of “bred dirty” tau-P301S mice and appropriate controls. At endpoint, we collected brain and spleen for flow cytometry, immunofluorescence, and bulk RNAseq. Results The proportions of CD3+ T cells, monocytes, and macrophages were significantly increased in the brains of the dirty tau-P301S mice compared to their clean tau-P301S counterparts. The brains of the dirty tau-P301S mice also showed an increase in the proportion of CD8+ T cells, specifically effector differentiated (CD62L-CD44+) CD8+ T cells. The proportion of activated (CD11c+) microglia was increased in tau-P301S mice but unaffected by dirty status. Conclusion Disease-associated infiltration of adaptive immune cells into the brain is amplified by dirty status without grossly affecting microglial activation. Given the increasingly recognized role of T cells in Alzheimer’s disease pathogenesis, our results suggest that more immune educated models might better represent the role of T cells in neurodegenerative disease. Funding Source Mayo Clinic and The Translational Genomics Research Institute Topic Categories Neuroimmunology (NEUR)
Anti‐amyloid nanobody‐Fc fusion protein drives potent amyloid clearance through microglial recruitment
Ding, Zonghui , Gibson, Katelin A. , Nascari, David , Tallant, Lauren E., Dickson, Dennis W., Fryer, John D., Nascari, David G , Tallant, Lauren , Bouchal, Samantha M. , Dickson, Dennis W. , Fryer, John Denis

Mayo Clinic

Alzheimer's & Dementia: Translational Research & Clinical Interventions | July 13, 2026 | Volume: 12 | Issue: 3 | Pages: No page available

10.1002/trc2.70269 | PMID 42444752 Get It

Abstract INTRODUCTION Anti‐amyloid beta (Aβ) monoclonal antibodies are effective at lowering amyloid in Alzheimer's disease (AD). However, whether Fc‐mediated effector function is absolutely required for efficacy is not completely understood. This is important for optimizing therapeutic efficacy and mitigating side effects such as amyloid‐related imaging abnormalities (ARIA). Antibodies lacking Fc effector function, like single‐domain antibodies (nanobodies), offer a unique tool to dissect these mechanisms, as their small size facilitates blood–brain barrier (BBB) penetration and allows Fc‐mediated functions to be studied independently. METHODS We immunized a llama with Aβ aggregates and constructed a phage display library to screen for aggregate‐specific nanobodies. Lead candidates were characterized by epitope mapping and binding affinity to amyloid plaques in both murine and human AD brain tissues. We further assessed their BBB permeability and evaluated their efficacy in clearing pre‐existing plaques in amyloid precursor protein (APP)/presenilin 1 (PS1) mice. RESULTS We identified two lead nanobodies, 3A11 and 2D10, that bind distinct epitopes and specifically bind Aβ plaques in murine and human AD brain tissues. Following systemic administration, the monovalent, unmodified (Fc‐less) 2D10 nanobody, but not 3A11, successfully crossed the BBB and engaged amyloid plaques in APP/PS1 mice. However, despite robust target engagement, the Fc‐less 2D10 failed to recruit microglia or reduce plaque burden. In contrast, an engineered 2D10‐Fc fusion antibody potently cleared amyloid plaques, achieving a reduction in pathology comparable to aducanumab treatment. This efficacy was directly correlated with Fc‐mediated microglial recruitment and activation, demonstrating that the Fc domain is essential for phagocytic plaque removal. DISCUSSION Our findings demonstrate that Fc effector function is indispensable for microglial‐mediated amyloid clearance in vivo. By clarifying this fundamental mechanism, this study provides a framework for the rational design of next‐generation immunotherapies. Furthermore, 2D10‐Fc represents a promising therapeutic candidate, combining the high‐affinity targeting of nanobodies with the effector power necessary for robust plaque clearance.
Amyloid exacerbates tau and alpha‐synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model
Rabichow, Benjamin E. , Nixon, Lacey, Tallant, Lauren E., Gibson, Katelin A. , Nascari, David , Barnett, J. Hudson, Massa, Nashali , Fryer, John D., Barnett, J. Hudson , Nascari, David G , Tallant, Lauren , Fryer, John Denis

Mayo Clinic

Alzheimer's & Dementia | July 3, 2026 | Volume: 22 | Issue: 7 | Pages: No page available

10.1002/alz.71639 | PMID 42394391 Get It

Abstract INTRODUCTION Neurodegenerative diseases often involve overlapping alpha‐synuclein (asyn), amyloid beta, and tau proteinopathies, yet the mechanisms, impact, and directionality of their interactions remain unclear. METHODS We induced brain‐wide neuronal asyn/tau pathologies via viral expression of wild‐type asyn, mutant asyn E46K , mutant tau A152T , or both asyn E46K /tau A152T in adult amyloidosis knock‐in mice and controls, either post‐plaque deposition (6 months old) or pre‐plaque (3 months old). Open‐field behavior was assessed baseline and 3 and 6 months post‐transduction, followed by neuropathology and neuroinflammation analyses. RESULTS Post‐plaque induction in amyloid mice increased asyn/tau total and phosphorylated levels and exacerbated amyloid‐related hyperlocomotion/anxiety. Pre‐plaque induction produced robust phosphorylated pathologies irrespective of amyloid, while causing similar amyloid‐dependent behavioral synergy. Tau pathology drove LGALS3 + inflammatory glial responses in white‐matter fibers. DISCUSSION Amyloid context gates vulnerability, with certain synergies manifesting across stages. White‐matter gliosis is a novel mechanism of tau A152T risk. Together, our data argue for the development of stage‐aware, multitarget interventions and biomarkers.
EGFR INHIBITION PROMOTES ENTEROENDOCRINE CELL DIFFERENTIATION CONTRIBUTING TO TREATMENT-ASSOCIATED DIARRHEA
Ramos, Guilherme Piovezani , Zeve, Daniel , Shepherd, Amy , Saint-Denis, Elisa, Aldefer, Olivia, Frintu, Bia, Dale, Stanley, Sharma, Karina, Mohlmann, Emma , Mannam, Prabhath , Byers, Morgan , Terzian, Jack, Ribeiro, Claudio D , Borges, Kleiton S., Carlone, Diana , Rao, M Prasada, Zeve, Daniel , Ribeiro, Claudio , Oliveira, Luiz Fernando , Borges, Kleiton Silva , O'Connell, Amy E , Carlone, Diana L , Duma, Narjust , Rao, Meenakshi , Breault, David T , Ramos, Guilherme P , Shepherd, Amy , Saint‐Denis, Elisa, Frintu, Bianca, Sharma, Karina, O’Connell, Amy E. , Florez, Narjust

Mayo Clinic

No container title available | June 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.02.729650 | PMID 42282735 Get It

ABSTRACT Enteroendocrine cells (EECs) are specialized sensors of the gastrointestinal (GI) epithelium that regulate gut function and systemic metabolism through hormone secretion. The molecular pathways directing intestinal stem cell (ISC) differentiation into EECs are incompletely understood due, in part, to their rarity. We sought to identify novel regulators of human EEC differentiation using a high-throughput screen of FDA-approved drugs and human duodenal organoids. Two epidermal growth factor receptor inhibitors (EGFRi) commonly used in cancer therapy and known to cause GI side effects, erlotinib and lapatinib, emerged as strong inducers of EEC differentiation, dramatically increasing chromogranin A (CHGA) expression compared to controls, while maintaining ISC function and organoid growth. EGFRi-treated organoids revealed robust and broad upregulation of EEC hormones, including serotonin (5HT), motilin (MLN), and somatostatin (SST), among others. In agreement with these findings, analysis of a patient cohort with lung cancer revealed an association with erlotinib use and increased circulating levels of the above EEC hormones compared to matched controls. Supporting a direct effect of EGFRi on EEC differentiation, mice treated with erlotinib demonstrated increased EEC numbers and hormones and showed EGFRi-associated diarrhea (EAD), a limiting side effect of these medications. Mechanistically, EGFRi induced upregulation of interferon (IFN) signaling targets during early ISC-to-EEC differentiation. Consistent with this, inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) attenuated EGFRi-induced EEC differentiation. These findings provide important insight into EEC differentiation that could inform treatment strategies for EAD, metabolic diseases, and GI diseases. Brief Summary Inhibition of EGFR signaling promotes human ISC-to-EEC differentiation through activation of STAT1 signaling.